2025 Obesity Drug Study: What the Research Shows

The landscape of obesity pharmacotherapy has changed dramatically over the past decade, but choosing the right treatment remains a complex clinical challenge. A sweeping new analysis published in The BMJ in July 2026 offers the most comprehensive head-to-head comparison of obesity medications to date — and the findings reveal important trade-offs that clinicians and patients alike need to understand. The study, conducted by Nong and colleagues, synthesized data from 262 randomized controlled trials involving nearly 100,000 participants, making it one of the largest and most rigorous evaluations of obesity pharmacotherapy ever undertaken.

What This Study Found

The network meta-analysis evaluated 19 obesity drugs across 24 clinical outcomes, with follow-up periods ranging from 12 to 172 weeks. Compared with lifestyle modification alone, researchers found substantial variation in weight loss efficacy at one year, with moderate to high certainty evidence supporting the following mean reductions in body weight:

• Tirzepatide: −14.9% (95% CI −16.0% to −13.9%)
• Cagrilintide-semaglutide (CagriSema): −14.8% (95% CI −16.9% to −12.7%)
• Oral semaglutide: −10.9% (95% CI −12.7% to −9.1%)
• Orforglipron: −9.9% (95% CI −12.4% to −7.5%)
• Subcutaneous semaglutide: −9.8% (95% CI −10.6% to −9.1%)
• Phentermine-topiramate: −8.1% (95% CI −9.7% to −6.5%)

Emerging agents — including ecnoglutide, mazdutide, and retatrutide — showed weight reductions ranging from 13.1% to 14.6%, though these estimates carry very low to low certainty due to more limited trial data.

Larger weight loss, however, did not come without cost. The study suggests that greater efficacy was generally accompanied by higher rates of discontinuation due to adverse events. Orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide all showed elevated discontinuation risk ratios ranging from 1.9 to 4.2 compared with placebo or lifestyle modification. Gastrointestinal adverse events were most pronounced with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide, with risk ratios between 3.1 and 4.2.

Fatigue risk was also notably elevated across several agents. Naltrexone-bupropion showed the highest fatigue signal, with a risk ratio of 8.9 — translating to an absolute increase of approximately 331 additional cases of fatigue per 1,000 people over one year. Orforglipron and CagriSema also showed meaningful fatigue increases (100 and 92 more per 1,000, respectively).

On body composition, tirzepatide produced the greatest reduction in fat mass at 25.7%, but researchers also found it reduced lean mass the most, by 8.3% — a finding with potential implications for long-term metabolic health and physical function that warrants further investigation.

Subcutaneous semaglutide stood out as the only agent associated with reduced all-cause mortality (risk ratio 0.81, 95% CI 0.72 to 0.93) and reduced myocardial infarction risk (0.72, 95% CI 0.61 to 0.85). The researchers note these estimates were largely informed by cardiovascular outcome trials conducted in high-risk populations. Both subcutaneous semaglutide and tirzepatide were associated with reduced heart failure risk (risk ratios 0.43 and 0.49, respectively).

Notably, no drug convincingly reduced kidney failure risk or improved quality of life beyond the minimally important clinical difference of 10 points on validated scales. Across 43 trials involving more than 45,000 participants, all mean differences in quality of life scores remained below 5 points.

Clinical Significance

For clinicians, this study provides a rare synthesis of comparative evidence that goes well beyond simple weight loss endpoints. The researchers employed the GRADE framework to assess certainty of evidence and used both frequentist random effects models and Bayesian dose-response models — methodological rigor that lends credibility to the conclusions.

One of the most clinically significant takeaways is the disconnect between weight loss magnitude and broader health outcomes. Tirzepatide produced the greatest weight reduction in the analysis, yet subcutaneous semaglutide was the only agent with demonstrated mortality and myocardial infarction benefits. This finding underscores a point that is increasingly recognized in obesity medicine: weight loss alone is not a sufficient surrogate for cardiometabolic benefit, and treatment selection should be informed by the patient's full clinical profile.

The lean mass reduction observed with tirzepatide also raises questions that the field has not yet fully resolved. Loss of muscle mass during weight loss is a well-documented concern, particularly in older adults and those at risk for sarcopenia. The clinical significance of an 8.3% reduction in lean mass alongside 25.7% fat loss requires careful interpretation within individual patient contexts.

The study also found that subgroup analyses for drug dosages and key patient characteristics did not identify credible differences in relative treatment effects — with the exception that longer trial durations were associated with greater weight reductions for subcutaneous semaglutide. This suggests that the comparative hierarchy of these drugs is relatively consistent across different patient populations studied to date, though real-world heterogeneity may tell a different story.

Current Access and Compliance Context

Understanding what the research shows is only part of the equation. In clinical practice, access, cost, insurance coverage, and adherence all shape treatment outcomes in ways that randomized trials cannot fully capture. Many of the highest-performing agents identified in this analysis remain subject to significant access barriers in the United States and globally, including drug shortages, high out-of-pocket costs, and variable insurance coverage.

Discontinuation rates observed in these trials are also meaningful. Even under the controlled conditions of a clinical trial — where participants typically receive monitoring and support — rates of treatment discontinuation due to adverse events were substantial for several leading agents. In real-world clinical settings, where follow-up may be less intensive, adherence challenges could further affect outcomes.

The oral formulations of newer agents, such as oral semaglutide and orforglipron, may offer practical advantages for patients who are needle-averse or face barriers to injectable therapies. However, the study suggests that oral agents in this analysis also carried meaningful gastrointestinal and discontinuation risks that clinicians should discuss proactively with patients.

The emergence of investigational agents such as retatrutide and mazdutide adds further complexity to clinical decision-making. While early signals are promising, the very low to low certainty ratings assigned by the researchers reflect the limited evidence base currently available for these compounds. Robust long-term data, including cardiovascular outcome trials, will be essential before these agents can be confidently incorporated into treatment hierarchies.

What Patients Should Know

If you are living with overweight or obesity and considering pharmacological treatment, this study offers several important evidence-based takeaways to discuss with your healthcare provider:

Bigger weight loss does not always mean better overall health outcomes. The drug that produced the greatest weight reduction in this analysis was not the same drug associated with reduced mortality or heart attack risk. Your treatment goals should extend beyond the number on the scale.

Side effects are common and vary by medication. Gastrointestinal symptoms and fatigue affected a meaningful proportion of participants across multiple drug categories. Knowing what to expect — and having a clear plan for managing side effects — can significantly affect whether you are able to stay on a treatment long enough to benefit.

Quality of life improvements were modest across all drugs studied. None of the medications evaluated produced quality of life improvements that exceeded the threshold considered clinically meaningful. This is an important finding that researchers suggest should factor into shared decision-making conversations between patients and providers.

Muscle mass loss is a real consideration. Particularly with the most potent weight loss agents, the study found significant reductions in lean mass alongside fat mass. Physical activity — particularly resistance training — may play an important role in preserving muscle during pharmacological weight loss treatment.

Long-term data for newer agents is still limited. Some of the most promising emerging treatments in this analysis had evidence rated as very low to low certainty. This does not mean they are ineffective — it means the evidence base is still developing, and longer-term safety and cardiovascular outcome data are still needed.

Conclusion

The 2026 BMJ network meta-analysis by Nong and colleagues represents a significant contribution to the evidence base guiding obesity pharmacotherapy. By analyzing 262 trials and nearly 100,000 participants, the study provides a detailed comparative picture of the benefits and harms associated with 19 obesity drugs — and consistently reinforces the message that treatment decisions should be individualized, evidence-informed, and made through shared decision-making between clinician and patient.

As the field continues to evolve rapidly, access to a knowledgeable, up-to-date healthcare provider is more important than ever. If you are interested in learning more about evidence-based obesity treatment options and finding a qualified clinician in your area, we encourage you to visit peptideassociation.org/find-a-doctor to connect with a provider who can help you navigate these complex treatment decisions safely and effectively.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The information presented reflects findings from the cited peer-reviewed research and should not be used as a substitute for professional medical consultation. Always speak with a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.

---

Citation: Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;e372161. doi:10.1136/bmj-2026-372161. PMID: 42419792.